Phase II study of low dose fixed rate infusion of gemcitabine with cisplatin and dexamethazone in resistant non- hodgkin lymphoma and correlation with MDR and BCL -2 expression /
Shereef Ahmed Elsammany
Phase II study of low dose fixed rate infusion of gemcitabine with cisplatin and dexamethazone in resistant non- hodgkin lymphoma and correlation with MDR and BCL -2 expression / دراسة الاستجابة للتنقيط الوريدى ذو المعدل الثابت لعقار الجمستابين مع السيزبلاتين و الديكساميثازون فى حالات الليمفوما من نوع غير الهودحكين غير المستجيبة للعلاج الكيميائى و علاقة وجود جين م.د.ر و جين ب س ل2 بالاستجابة لهذا البرنامج العلاجى Shereef Ahmed Elsammany ; Supervised Mostafa Mahmoud Elserafy , Sameh Sayed Ahmed Shamaa , Mona Ali Sakr - Cairo : Shereef Ahmed Elsammany , 2010 - 202P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
Despite significant advances in the managment of patients with aggressive non - hodgkin's lymphomas (NHLs) significant proportion of patients still experience relapse following initial response to therapy or even not responding to chemotherapy from the start . So there is a great priority for the development of new chemotherapy regimens in addition to new prognostic factors for respone and survival in patients with resistant disease
Fixed rate Gemcitabine N.H.L
Phase II study of low dose fixed rate infusion of gemcitabine with cisplatin and dexamethazone in resistant non- hodgkin lymphoma and correlation with MDR and BCL -2 expression / دراسة الاستجابة للتنقيط الوريدى ذو المعدل الثابت لعقار الجمستابين مع السيزبلاتين و الديكساميثازون فى حالات الليمفوما من نوع غير الهودحكين غير المستجيبة للعلاج الكيميائى و علاقة وجود جين م.د.ر و جين ب س ل2 بالاستجابة لهذا البرنامج العلاجى Shereef Ahmed Elsammany ; Supervised Mostafa Mahmoud Elserafy , Sameh Sayed Ahmed Shamaa , Mona Ali Sakr - Cairo : Shereef Ahmed Elsammany , 2010 - 202P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
Despite significant advances in the managment of patients with aggressive non - hodgkin's lymphomas (NHLs) significant proportion of patients still experience relapse following initial response to therapy or even not responding to chemotherapy from the start . So there is a great priority for the development of new chemotherapy regimens in addition to new prognostic factors for respone and survival in patients with resistant disease
Fixed rate Gemcitabine N.H.L